I am a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the OSUCCC – James, where I've been a faculty member since 2005. I completed my gynecologic oncology fellowship at Yale University and my residency at Case Western Reserve University (MetroHealth) and the Cleveland Clinic Foundation. I attended medical school at Wayne State and earned my undergraduate degree at the University of Notre Dame.
I am the director for clinical research in gynecologic oncology, as well as the co-director of the gynecologic oncology phase I program. I also serve as the ORIEN physician liaison for The Ohio State University Comprehensive Cancer Center. I am active nationally as a committee member for the NCI Gynecologic Cancer Steering Committee’s Ovarian Task Force, NRG Oncology (Ovarian Cancer and Developmental Therapeutics Groups), the Society of Gynecologist Oncology and the American Society of Clinical Oncology. My passion for improving the care of patients with gynecologic cancers and my expertise in ovarian cancer resulted in my appointment to the panel of the National Comprehensive Cancer Network (NCCN) Guidelines for Ovarian Cancer, where I continue as an active participant.
As a member of the Translational Therapeutics Program at the OSUCCC – James, my research is focused on identifying novel and innovative therapies for gynecologic cancers. I have designed, coordinated and published on all levels of clinical trials to include phase I, II and III studies with a special interest in novel compounds. I continue to work to improve the therapies (novel techniques/targets/immune therapy) as well as identify patients who would benefit (or not benefit) from different treatment options in ovarian and uterine cancer (specifically high-risk histologies) while minimizing side effects.
The quest to improve patient outcomes has led me to my work on improving surgical techniques. Robotic-assisted, minimally invasive surgical techniques have been implemented in all aspects of practice, resulting in the publication of the improved outcomes and as an instructor on these techniques at a national level.
I am honored and humbled to help care for the amazing women who are my patients and their families. Improving the care of women with gynecologic cancer through research has led to me being recognized with over 100 publications in the most respected scientific journals, including New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, JAMA Oncology and Nature Genetics.
My compassionate nature and communication has been recognized with patient satisfaction that ranks at the very top for the country. My accomplishments have also resulted in being named as one of the Best/Top Doctors in America by U.S. News and World Report (Castle Connelly) and Best Doctors for multiple years. However, my greatest pride comes from my family, including my beautiful wife and our five amazing children.
- Named to the Castle Connolly list of “Regional Top Doctors,” 2011–2021
- Rated in the top 10 percent of physicians in the nation for patient satisfaction, 2014, 2016, 2017, 2018 and 2019
- Best Doctor in America, 2017
Procedures and Conditions I Treat
- Soft Tissue Cancers
- Endometrial Cancers
- Cervical Cancer
- Vulvar Cancers
- Vaginal Cancers
- Gynecologic Cancers
- Uterine Cancers
- Ovarian Cancers
- Minimally Invasive Surgical Procedures
- Women's Health
- Peritoneal Cancers
- Reproductive Health
Locations Where I Practice
3691 Ridge Mill Drive
Hilliard, OH 43026
Please note: Not all physicians schedule patients at each listed location.
Education and Training
Wayne State University School of Medicine, Detroit, MI
8/1/1994 - 6/30/1998
Case Western Reserve University, Cleveland, OH
7/1/1998 - 6/30/1999
Case Western Reserve University, Cleveland, OH
7/1/1999 - 6/30/2002
Yale University School of Medicine, New Haven, CT
7/1/2002 - 6/30/2005
Obstetrics & Gynecology
The overall patient satisfaction rating is an average of all patient responses to the six doctor communication related questions shown below from the Clinician and Group Consumer Assessment of Healthcare Providers and Systems survey. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page.
The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of Ohio State Wexner Medical Center.
129 Patient Satisfaction Reviews
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 09/30/2022, Dr. O'Malley has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- Clovis Oncology
- Corcept Therapeutics
- Eisai, Inc.
- Exelixis, Inc.
- Merck & Co., Inc.
- Xencor Inc
- Regeneron Pharmaceuticals
- Roche Diagnostics
- Immunogen, Inc.
- GOG Foundation, Inc.
- Jazz Pharmaceuticals
- Trillium Therapeutics, Inc.
- Mersana Therapeutics
- Arcus Biosciences
- SDP Oncology
- Atossa Therapeutics
- Duality Bio
- Myriad Genetics
- Onconova Therapeutics
- Umoja BioPharma
- VBL Therapeutics
- Vincerx Pharma
- Zentalis Pharmaceuticals, Inc